Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis

Carmen M. Stanca, Nancy Bach, Jorge Allina, Carol Bodian, Henry Bodenheimer, Joseph A. Odin

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Statin treatment reduces hypercholesterolemia and may be anti-inflammatory. Case reports noted decreased alkaline phosphatase and histological improvement following statin treatment in primary biliary cirrhosis. The objective of this study was to assess the long-term effects of statin treatment in primary biliary cirrhosis. A retrospective analysis compared clinical and biochemical data from 15 hypercholesterolemic individuals with primary biliary cirrhosis who were treated long-term with atorvastatin with an age and gender matched, primary biliary cirrhosis control group. A significant decrease in total cholesterol and low-density lipoprotein (LDL)-cholesterol (p ≤ 0.002) was observed throughout atorvastatin treatment (median time 2.5 years). LDL-cholesterol levels in the control group were not significantly changed after 2 years (p > 0.050). No significant changes were noted in alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin and Mayo Risk Score in either group (p > 0.05). Long-term atorvastatin treatment reduced LDL-cholesterol in primary biliary cirrhosis, but there was no evidence of any anti-inflammatory effect.

Original languageEnglish
Pages (from-to)1988-1993
Number of pages6
JournalDigestive Diseases and Sciences
Issue number7
StatePublished - Jul 2008


  • Biliary
  • Cholesterol
  • Hydroxymethylglutaryl-coA reductase inhibitors
  • Hyperlipidemias
  • Immunosuppression
  • Liver cirrhosis


Dive into the research topics of 'Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis'. Together they form a unique fingerprint.

Cite this